Last
Update:
May 26, 2010
* Perinatal data are
the Perinatal Data Page
** Pediatric data are in
the Pediatric Data Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
4th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
Wit F, Phanuphak P, Ruxrungtham K, et al
Abstract
Risk factors for nevirapine-associated rash among HIV-infected patients
with low CD4 cell
counts in resource-limited setting
Kiertiburanakul S, Sungkanuparph S,
Charoenyingwattana A, et al
Abstract
24-week efficacy and safety of nevirapine: 400 mg versus 600 mg based
HAART in HIV-infected
patients with active tuberculosis receiving rifampicin
Manosuthi W, Avihingsanon A, Kantipong P, et
al
Abstract
Incidence of nevirapine-associated hypersensitivity reactions is
different in patients with
prior treatment experience compared to treatment-naïve patients: the
ATHENA cohort study
Wit F, Kesselring A, Gras L, et al
Abstract
Use of the ELISpot assay to detect abacavir- and nevirapine-induced IFN-g
responses in PBMC
from HIV-infected patients with abacavir or nevirapine hypersensitivity
reactions
Keane N, Lucas A, Netto J, et al
Abstract
History of drug allergy associated with nevirapine toxicity among AIDS
patients with low
baseline CD4 count
Maek-a-nantawat W, Tansuphaswadikul S,
Eindani Aung S, et al
Abstract
XVI International AIDS Conference
|
-
Nevirapine is detectable in breast milk up to 2 weeks after single
dose
A. Kunz, K. Mugenyi, H. Karcher, et al
Abstract
-
An indication of nevirapine (012 regime) failure in a programme
setting in Malawi
G. Kamanga, C. Zimba
Abstract
-
Pharmacokinetic interaction between itraconazole and nevirapine in
healthy volunteers
S. Jaruratanasirikul, S. Sriwiriyajan
Abstract
-
Effectiveness of nevirapine in reducing mother to child transmission
of HIV in a non clinical trial setting,
Zimbabwe, 2005
A. Muchedzi, M. Tshimanga, D. Jones, et al
Abstract
-
Injectable sustained release nevirapine, designed to be
co-administered in programs of
accelerated DPT immunization, for the prevention of mother-to-child
HIV transmission associated
with breast feeding
T. Smith, J.L. Sullivan, M. Neely, et al
Abstract
-
Long term efficacy and tolerability of nevirapine based first-line
regimens in HIV-1-infected adults
L. Cuzin, M. Biboulet, P. Pugliese, et al
Abstract
-
Incidence and characteristics of Nevirapine - related rash among
HIV-infected patients with severe
immunosupression and initial full-dose Nevirapine
J. Claros, J.A. Collins, C. Rojas
Abstract
-
HAART with initial full-dose Nevirapine is not associated with higher
risk of rash among HIV
patients with severe immunosupression
J.A. Collins, J. Claros, L. Hercilla
Abstract
-
Mucosal exposure to HIV-1 does not lead to intrapartum transmission
after nevirapine single dose
A. Kunz, K. Mugenyi, H. Karcher, et al
Abstract
-
Clonal analysis of the diversity in drug resistant subtype C HIV-1
after single dose nevirapine
S. Kassaye, E. Lee, B. Johnston, et al
Abstract
-
Nevirapine concentrations in HIV-infected children treated with
divided fixed dose combination
tablets in Malawi and Zambia
V. Mulenga, J. Ellis, F. Ewings, et al
Abstract
-
Cost of multi-dose antiretroviral (ARV) versus single-dose nevirapine
treatment for prevention of
mother-to-child HIV transmission (pMTCT) in the Dominican Republic
(DR): potential savings
associated with greater efficacy
J. Roman-Pouriet, N. Kley, A.D. Fernandez, et al
Abstract
-
Pharmacokinetic profiling and bioequivalence assessment of two
marketed brands of Nevirapine
tablets in 18 healthy volunteers
E. Mahler, D. Fridman, C. Monzón, et al
Abstract
-
Effectiveness of single dose nevirapine or azt in preventing HIV
transmission from mother to child
R. Navuga, R. Kizito, A. Nalubowa, et al
Abstract
-
Immune restoration syndrome (IRS) as a surrogate marker for
immunologic response to generic,
nevirapine-based V.S. to efavirenz- based antiretroviral regimens
O. Putcharoen, C. Suankratay, T. Tantawichien, et al
Abstract
-
Resistance induced by the use of single dose nevirapine (sdNVP) for
prevention of mother-to-child
transmission of HIV (PMTCT): debate and reality, experience in Nigeria
J. Mandala, A. Abutu, L. Anomnachi, et al
Abstract
-
Can routine alanine transaminase (ALT) monitoring be simplified in
patients starting a nevirapine
containing antiretroviral treatment regimen? An experience from a
clinic setting in Maputo, Mozambique
S. Mikusova, M. Biot, R. Bastos, et al
Abstract
-
Hepatotoxicity in injection drug users (IDUs) and non-IDUs receiving
nevirapine-based HAART
H. Tossonian, J. Raffa, J. Grebely, et al
Abstract
-
Virological and immunological response after naive HIV-infected
patients who received
nevirapine -based antiretroviral Therapy
N. Chumpathat, S. Likanonsakul, B. Kowadisaiburana, et al
Abstract
-
Immunological and virological response after naive HIV-infected
patients who received nevirapine-based
antiretroviral therapy
N. Chumpathat, S. Likanonskul, B. Kovadisaiburana, et al
Abstract
-
Generic fixed-dose combination of nevirapine, stavudine, and
lamivudine: 2-year assessment in Cameroon
S. Koulla-Shiro, C. Laurent, C. Kouanfack, et al
Abstract
-
Incidence of rash and severe hepatotoxicity in patients switching from
a protease inhibitor (PI) or
efavirenz (EFV) to nevirapine (NVP) at relatively high CD4 count
levels
A. De Roo, F. Moerman, L. Lynen, et al
Abstract
-
Risk of discontinuation of nevirapine due to
toxicities in
antiretroviral naive and
experienced patients
with high and low CD4 counts
A. Mocroft, K. Lacombe, J. Rockstroh, et al
Abstract
-
Challenges of nevirapine toxicity at the antiretroviral centre in Jos,
Nigeria
G. Onwuegbuzie, O. Agbaji, T. Babafemi, et al
Abstract
-
Efficacy and safety of nevirapine versus efavirenz when combined in
ART regimens in HIV-infected
antiretroviral-naïve persons (the NNRTI substudy of FIRST-CPCRA 058)
M. van den Berg-Wolf, G. Peng, Y. Xiang, et al
Abstract
-
Nevirapine-associated hepatic toxicity among HIV-1-seropositive
pregnant women in Mozambique
L. Jamisse, J. Balkus, J. Hitti, et al
Abstract
-
Maternal immune response and clinical outcomes on NNRTI-based
antiretroviral therapy (ART) following
exposure to single-dose nevirapine (NVP) for prevention of
mother-to-child HIV transmission (PMTCT)
B. Chi, M. Sinkala, J. Levy, et al
Abstract
-
Morbidity profiles among patients on generic nevirapine, zidovudine
and lamivudine for the treatment of
AIDS in a resource-limited setting
L. Zijenah, G. Kadzirange, N. Gonah, et al
Abstract
-
Elimination kinetics of single 200 mg dose of oral nevirapine in
HIV-1-infected pregnant Indian women
R.B. Mhatre, P.A. Thakur, S. Dalvi, et al
Abstract
-
Incidence and predictors of hepatotoxicity among patients receiving
nevirapine (NVP)-containing
antiretroviral therapy (ART) in Zambia
R. Cantrell, B. Chi, L. Mulenga, et al
Abstract
-
Efficacy and tolerability of nevirapine-based regimen VS
efavirenz-based regimen in HIV-infected
Thai children
K. Lapphra, N. Vanprapar, S. Chearskul, et al
Abstract
-
Analysis of hepatic events after nevirapine containing regimens in the
real life by CD4+, gender and
HCV co-infection. Results from a single centre study
C. Torti, G. Lapadula, M. Puoti, et al
Abstract
-
24 month outcome of nevirapine based highly active antiretroviral
therapy (HAART) in women during
the postpartum period: a PMTCT+ pilot program supported by the Global
Fund in Thailand
G. Jourdain, N. Briand, F. Fregonese, et al
Abstract
-
Adverse reactions related to antiretroviral regimen containing
nevirapine used by HIV-infected
pregnant women from the maternal and perinatal cohort of Belo
Horizonte, Brazil
R.A.L.P. Aguiar, V.H. Melo, I.K.D.Cavallo, et al
Abstract
-
Toxicity of nevirapine in HIV-infected women with high CD4 counts in
Malawi: the BAN study
B. Bramson, C. Chasela, C. Chavula, et al
Abstract
-
How to target TOPS: Combivir to reduce nevirapine-resistance after
PMTCT: a stochastic model
D. Westreich, A. Van Rie
Abstract
|
Ninth International Congress on Drug Therapy
in HIV Infection |
-
Impact
of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as
tablets and capsules
in
African patients
C Kityo, AS Walker, F Lutwana,
et al
PDF Abstract
-
Lipid changes in patients receiving nevirapine (NVP) in combination with
tenofovir/emtricitabine:
results from the CCIAT trial
Davis C, Talwani R, Gilliam B, Amoroso A, et
al
Abstract
-
Nevirapine (NVP),
tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC) is effective and
well tolerated
in naïve HIV-1 infected patients
Bickel M, Gute P, Carlebach A, et al
Abstract
-
Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapies
Rodriguez-Arrondo F, Aguirrebengoa K, Portu
J, et al
Abstract
-
Different metabolic and
anthropometric characteristics of TVD, CBV or KVX associated with nevirapine: |
Results from the "NEVIRAPINE COMPANION" cohort
Guaraldi G, Adorni F, Zona S, et al
Abstract
-
Substitution of nevirapine
for efavirenz in virologically controlled patients intolerant of efavirenz
Ward DJ, Curtin JM, Miller EJ, et al
Abstract
|
9th Int. Workshop on Clinical Pharmacology of
HIV Therapy |
-
PRESENTATION
Total and unbound nevirapine pharmacokinetics in HIV-infected children treated
with divided fixed-dose
combination tablets in Malawi.
Else LJ, Pollock L, Poerkson G, et al
PDF Presentation
-
PRESENTATION
Factors influencing efavirenz and nevirapine plasma concentration:
effect of ethnicity, weight and comedication.
Stoehr W, Back D, Dunn D, et al
PDF Presentation
-
POSTER
Factors influencing efavirenz and nevirapine plasma
concentration: effect of ethnicity, weight and comedication.
Stoehr W, Back D, Dunn D, Sabin C, Winston A,
PDF Poster
-
Identification of Nevirapine-resistant HIV-1 in the Latent Reservoir
following Single-dose Nevirapine
M Wind-Rotolo, C Durand, L
Cranmer, et al
Abstract
-
POSTER
Risks Associated with Nevirapine Use in Pregnant and Non-pregnant Women
E Aaro, M Kempf, S Criniti, et al
PDF
Poster
Abstract
-
Low
Hepatoxicity in Patients Randomized to Switching to Nevirapine Once Daily vs
Continuing
with
Nevirapine Twice Daily
D Podzamczer, M Olmo, J Sanz, et al
Abstract-
Dynamics
of Nevirapine-resistant HIV-1 following Single-dose NVP Assessed in Plasma and
Cells by
Consensus Sequencing and Oligonucleotide Ligation Assay
C Kress, T Wagner N
Ngo-Giang-Huong, et al
Abstract -
Mechanism by which N348I in HIV-1 Reverse Transcriptase Confers Dual
Zidovudine/Nevirapine
Resistance
Cremer, G Tachedjian
Abstract-
NNRTI,
Efavirenz and Nevirapine, Induce Leukocyte-Endothelial Cell Interactions in the
Microvasculature
M Andrade, F Baixauli, A Blas-Garcia, et al
Abstract
-
Pharmacokinetics of Nevirapine and Rifampicin in TB/HIV Co-infected
Patients in Burkina Faso
A Matteelli, N Saleri, M Regazzi, et al
Abstract
-
Effectiveness of NNRTI-containing ART in Women Previously Exposed to a
Single Dose of
Nevirapine: A Multi-country Cohort Study
P Weidle, J Stringer, M McConnell, et al
Abstract
-
Nevirapine Administered Once Daily Is as Efficient as a Twice-daily
Dosing. A Collaborative
Cohort Study
A Calmy, A Nguyen, J Lange, et al
Abstract
-
POSTER
Nevirapine Pharmacokinetics in Thai
Children Receiving either an Adult or Pediatric Fixed-dose |
Combination of Stavudine, Lamivudine, and Nevirapine
K Chokephaibulkit, T Cressey, W Prasitsuebsai, et al
PDF Poster
Abstract
-
POSTER
Nevirapine Exposure with WHO Pediatric Weight Band Dosing--Enhanced
Therapeutic Concentrations
Predicted Based on Extensive International Pharmacokinetic Experience
E Capparelli, D Kabamba, T Cressey, D Burger
PDF Poster
Abstract
-
POSTER
Comparison of Adverse Fetal Outcomes in
HIV-1-infected Antiretroviral-naïve Pregnant Women
Who Have Received Combivir and Either Nevirapine or Nelfinavir for
Prevention of Mother-to-Child
Transmission Antenatally
R Masaba, R Ndivo, I Nyangau, et al
PDF
Poster
Abstract
-
POSTER
Low Birth Weight with Nevirapine-based ART in Abidjan, Côte d’Ivoire: The
ANRS Ditrame Plus
Cohort and MTCT-Plus Initiative, 2001 to 2007
DK Ekouevi, B Tonwe-Gold, R Becquet, et al
PDF Poster Abstract
-
POSTER
Intrapartum Tenofovir and Emtricitabine Reduces
Development of Low-level NNRTI Resistance
following Ingestion of Single-dose Nevirapine for Perinatal HIV Prevention
B Chi, L Frenkel, G Aldrovandi, et al
PDF Poster Abstract
-
POSTER
Emergence and Fading of Nevirapine Resistance after First versus Repeated
Use of Single-dose
Nevirapine for Prevention of Mother-to-Child HIV Transmission: Women and
Infants in the Repeat
Pregnancy Study in Uganda
S Eshleman T Flys, M McConnell
PDF
Poster
Abstract
-
POSTER
Risks Associated with Nevirapine Use in Pregnant and Non-pregnant Women
E Aaro, M Kempf, S Criniti, et al
PDF
Poster
Abstract
-
POSTER
Analysis of NVP Resistance in Ugandan Infants Who Were HIV-infected
despite Receiving
Single-dose Nevirapine vs Single-dose NVP Plus up to 6 Weeks of Daily NVP
to Prevent HIV
Vertical Transmission
J Church, S Omer, L Guay, et
al
PDF Poster
Abstract
|
|
Compared hepatotoxicity of the two available non-nucleoside reverse
transcriptase inhibitors
in a
cohort of HIV-infected patients naïve to either efavirenz or nevirapine
Manfredi R., Calza L., Chiodo F.
Abstract
Therapeutic Drug Monitoring (TDM) For Nevirapine (NVP) In A Once Dosing
Regimen
(OD) In HIV Patients Who Had Interrupted Antiretroviral Therapy (TARV): 48
Weeks
Of
Follow Up
Martinelli C., Fiorelli C., Giuntini R., Leoncini F.
Abstract
Increasing nevirapine dose can overcome reduced bioavailability due to
rifampicin co-
administration
Ramachandran G., Hemanth Kumar A.K., Rajasekaran
Abstract
Results from pilot quality control program of generic antiretrovirals: content
and
dissolution analysis of generic nevirapine (HIV-NAT026).
Autar R.S., Sankote J., Mahanontharit A., et al
Abstract
Evaluation of Nevirapine Permeability and Retention in HIV-1 Cell Free and
Budded
Virions
Costa L., Aguiar R., Pereira H., Brindeiro R., Tanuri A
Abstract
NRTI
Sparing Trial (CTN 177): Antiviral and metabolic effects of nevirapine (NVP) +
lopinavir/ritonavir (LPV/r) vs. zidovudine/lamivudine (AZT/3TC) + NVP vs.
AZT/3TC + LPV/r
Harris M., Ochoa C., Allavena C., et al
Abstract
Tolerance of full dose nevirapine switch from efavirenz in HIV-infected
patient in Cambodia
Fernandez M., Laureillard D., Prak N., et al
Abstract
TB/HIV co-infected patients on rifampicin containing treatment have equivalent
ART
treatment outcomes, and concurrent use of nevirapine is not associated with
increased
hepatotoxicity
Van Cutsem G., Cohen K., Bedelu M., et al
Abstract
Risk
of liver toxicity in HCV/HIV coinfected patients with advanced chronic liver
disease
or
cirrhosis receiving nevirapine, efavirenz or lopinavir/r
Casado J., Aranzabal L., Moya J., et al
Abstract
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in
Patients with
Human
Immunodeficiency Virus Infection: Definitive Three-Year Results of the NEFA
Study.
Martínez E., Arnaiz J.A., Podzamcer D., et
al
Abstract
6th
International Workshop on Clinical
Pharmacology
of HIV Therapy |
-
PDF POSTER
Effect of pregnancy on Nevirapine pharmacokinetics during chronic therapy
Caparelli, E
PDF
Poster
Community-based Generic Antiretroviral Therapy following
Single-dose Nevirapine or
Short-course AZT in Zimbabwe
L Zijenah, G Kadzirange, S Rusakaniko, et al
PDF
Poster
Abstract
POSTER
Clonal Analysis of Drug-resistant Mutations in Plasma
and Breast Milk following
Single-dose Nevirapine
E Lee, R Kantor, E Johnston, et al
PDF
Poster
Abstract
POSTER
Hepatotoxicity Associated with
Nevirapine Use in HIV-infected Children
M Baylor, O Ayime, M
Truffa, et al
PDF Poster
Abstract
Hepatotoxicity Associated with
Nevirapine Use in HIV-infected Children
M Baylor, O Ayime, M
Truffa, et al
Abstract
Selection of Resistance Mutations in Children
Receiving Prophylaxis with Lamivudine or
Nevirapine for the Prevention of Postnatal
Transmission of HIV
M Giuliano, C
Galluzzo, E Germinario, et al
Abstract
Comparison of Nevirapine Resistance in Women with Subtype C Compared
with Subtypes
A and D after Single-dose NVP
SH Eshleman, D Hoover, S Chen, et al
AbstractPharmacogenetics of Nevirapine and Hepatotoxicity:
NWCS220, an ACTG Collaborative Study
DW Haas, J Bartlett, J Andersen, et al
Abstract
Minimum Plasma Concentrations of Nevirapine and Efavirenz in Relation to
Virologic
Failure in Antiretroviral-naive Patients
F van Leth, B Kappelhoff, D Johnson, et
al
Abstract
A Comparison of Toxicity in Nevirapine- vs Protease
Inhibitor-containing HAART Regimens
in Pregnant Women
D Money, D Khoo, G MacDonald,
et al
AbstractControversies in the Use of Nevirapine for Prevention
of Mother-to-Child Transmission
J McIntyre
Abstract
Efficacy of Peripartum Nevirapine to Prevent Mother to Child HIV
Transmission in Women
Presenting Late for Antenatal Care in Thailand
G Jourdain, S Le Coeur, N Ngo-Giang-Huong,
et al
Abstract
Infant Zidovudine Prophylaxis and Emergence of Nevirapine Resistance
at 6 Weeks in
Perinatally HIV-infected Infants Exposed to Intra-partum or Newborn
Nevirapine
N Ngo-Giang-Huong, G Jourdain, P Tungyai,
et al
Abstract
Sensitive Drug Resistance Assays Reveal Long-term Persistence of
HIV-1 Variants with
the K103N Nevirapine-resistance Mutation in Some Women and
Infants after Single-dose
NVP: HIVNET 012
S Eshleman, D Nissley, C Claasen, et
al
Abstract
Maternal Single-dose Nevirapine
May Not Be Needed to Reduce
Mother-to-Child HIV
Transmission in the Setting of
Maternal and Infant Zidovudine
and Infant Single-dose
Nevirapine: Results of a
Randomized Clinical Trial in
Botswana
R
Shapiro, I Thior, P Gilbert, et
al
Abstract
Preliminary Findings: Incidence of Serious Adverse Events
Attributed to Nevirapine among
Women Enrolled in an Ongoing Trial Using HAART tor Prevent
Mother-to-Child HIV
Transmission
T Thomas, P Amornkul, J Mwidau,
et al
Abstract
Nevirapine Resistance and Survival
of Women Receiving HAART Subsequent
to Prevention
of Mother-to-Child Transmission: A
Population-based Stochastic Model
D
Westreich , A Van Rie, F Behets, et
al
Abstract
Association of Cord Blood Nevirapine
with Self-reported Timing of Dose
and HIV-1
Transmission in the HIV NET 012
Study
B
Jackson, T Parsons, P Musoke, et al
Abstract
Effectiveness of
Single-dose Nevirapine in a Second
Pregnancy
N Martinson, L Pumla, L
Morris, et al
Abstract
Sensitive Real-Time PCR
Quantification of 103N Resistance Mutants
following Single-dose Treatment with
Nevirapine
S Loubser, P Balfe, G
Sherman, et al
Abstract
Persistence of NNRTI-r Resistant Variants after
Single-dose Nevirapine in HIV-1 Subtype-
C-infected Women
S Palmer , V Boltz , F Maldarelli, et al
Abstract
Resistance Emerges in the Majority of
Women Provided Intrapartum Single-dose Nevirapine
J
Johnson, J F Li, L Morris, et al
Abstract
-
What is the clinical relevance of the drug
interaction between nevirapine and rifampicin?
R Autar, A Mahanontharit, T Anekthananon, et al
Abstract-
Large Nevirapine cohort: 7% discontinuation due to
Hepatotoxicity
C Koegl, E Wolf, N Ruemmelein, et al
Abstract-
Clinical pharmacology of nevirapine (NVP) in
HIV-positive subjects with and without
HBV/HCV co-infection
S Garazzino, L Almond, S Bonora, et al
Abstract-
Economic model of first-line antiretroviral (ARV) strategies in ARV-naïve patients: comparing
ARV drug cost of a fixed-dose
combination (FDC) of nevirapine (NVP) to an efavirenz
(EFV) -based
regimen
in Thailand
P Keiser, R Lyu, C Donnelly, A Amend Kwasnik
Abstract-
Week 2 - Nevirapine (NVP) plasma levels are
associated with NVP-related toxicity
E Wolf, N Ruemmelein, C Hoffmann,
et al
Abstract-
Determination of subclinical atherosclerosis in
patients on long-term nevirapine,
efavirenz,
and
protease inhibitor-based
antiretroviral therapy by ultrasound measurement of
carotid artery
intima-media
thickness and multislice cardiac CT measurement of coronary
artery calcium
G Pierone, N Cho, J Norconk, et
al
Abstract
-
Nevirapine toxicity in the obstetrical population
when used in combination with other
antiretrovirals
A Gonzalez-Garcia, M I Fernandez, A Cotter, et al
Abstract -
Fixed-dose combination tablets of nevirapine, lamivudine, and stavudine
P Srinarong, S Prayngam, P Chunhacha, et al
Abstract -
Readily dispersed nevirapine for oral suspension
S Watnasirichaikul, S Panchon, P Thaunsukon, et al
Abstract -
Pharmacokinetics of nevirapine in HIV-HCV-coinfected
patients
L Héripret, T Lavrut, J Durant, et al
Abstract -
Effect of fluconazole on nevirapine pharmacokinetics
J Geel, J A Pitt, C J Orrell, et al
Abstract -
Therapeutic drug monitoring (TDM) of nevirapine
(NVP) in treatment-naive patients:
18 month
results from ATHENA
KML Crommentuyn, A D R Huitema, K Brinkman, et al
Abstract -
Cutaneous adverse drug reactions to nevirapine in a
cohort of 200 patients: clinical
spectrum and results
of treating through
hypersensitivity reactive patients
E Caumes, L Roudière, R Landman, et
al
Abstract -
Nevirapine related toxicity in a Nigerian patient receiving a fixed dose
drug combination
pill:
considerations in an era of rapidly expanding access to antiretrovirals
(ARVs) in
resource poor nations.
A Krain, O Daniel, S Ogun, et al
Abstract -
Plasma and intracellular levels of nevirapine in HIV
infected patients by immunoassay
S Azoulay, M C Nevers, C Creminon, et
al
Abstract -
Tolerability and adverse events of nevirapine
containing antiretroviral drugs in Gombe,
North East Nigeria.
WE Isaac, A S Shehu, A A Ali, Y B Jibrin
Abstract -
The Confort study: A randomised and controlled open
trial of efficacy and safety of
switching protease
inhibitor to nevirapine
in patients with undetectable viral load
M Gorgolas, JC Bernaldo de Quirós, et al
Abstract -
Predisposition to nevirapine hypersensitivity
associated with HLA-DRB1*01 and higher
CD4+ T cell
counts
A Martin, P Cameron, D Nolan, ,
et al
Abstract
-
Increase in high-density lipoprotein cholesterol when using nevirapine
and/or efavirenz is
maintained
up to 2 years
F van Leth, D Hall, J M A Lange, P Reiss
Abstract
|
|
4th
IAS Conference